| Dr John G Hay, MBBS, MD | |
|
111 Broadway Fl 2, New York, NY 10006-1995 | |
| (212) 263-9700 | |
| Not Available |
| Full Name | Dr John G Hay |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 46 Years |
| Location | 111 Broadway Fl 2, New York, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548200819 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 199120 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bellevue Hospital Center | New york, NY | Hospital |
| New York University Langone Medical Center | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New York University | 1355232422 | 4431 |
| New York City Health And Hospitals Corporation | 4183535305 | 239 |
News Archive
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.
How do you measure the pain of a patient who can't communicate? A Rhode Island Hospital researcher studied an observational pain scale in cardiac surgery patients, and found that the Critical-Care Pain Observation Tool (CPOT) provided an accurate measure of a patient's pain level.
The thrombolytic drug alteplase, despite recent concerns, is safe and effective in routine clinical use when used within 3 hours of stroke onset, according to an observational study published in this week's issue of The Lancet.
A researcher at Montana State University has called for an innovative, new approach in developing a vaccine against genital herpes.
› Verified 7 days ago
| Entity Name | New York City Health And Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548208127 PECOS PAC ID: 4183535305 Enrollment ID: O20040322001521 |
News Archive
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.
How do you measure the pain of a patient who can't communicate? A Rhode Island Hospital researcher studied an observational pain scale in cardiac surgery patients, and found that the Critical-Care Pain Observation Tool (CPOT) provided an accurate measure of a patient's pain level.
The thrombolytic drug alteplase, despite recent concerns, is safe and effective in routine clinical use when used within 3 hours of stroke onset, according to an observational study published in this week's issue of The Lancet.
A researcher at Montana State University has called for an innovative, new approach in developing a vaccine against genital herpes.
› Verified 7 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.
How do you measure the pain of a patient who can't communicate? A Rhode Island Hospital researcher studied an observational pain scale in cardiac surgery patients, and found that the Critical-Care Pain Observation Tool (CPOT) provided an accurate measure of a patient's pain level.
The thrombolytic drug alteplase, despite recent concerns, is safe and effective in routine clinical use when used within 3 hours of stroke onset, according to an observational study published in this week's issue of The Lancet.
A researcher at Montana State University has called for an innovative, new approach in developing a vaccine against genital herpes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John G Hay, MBBS, MD 423 E 23rd St, New York, NY 10010-5011 Ph: (212) 686-7500 | Dr John G Hay, MBBS, MD 111 Broadway Fl 2, New York, NY 10006-1995 Ph: (212) 263-9700 |
News Archive
Cancer Therapeutics, a company focused on translating cancer biology research into novel treatments for cancer, today announced the validation and performance of a new targeted drug, CTx-294886, in combination with Avastin™ (bevacizumab – Genentech/Roche) in a preclinical model of breast cancer. At the same time the Company announced that it has developed a new High Throughput Screening (HTS) platform for the identification of small molecule inhibitors of protein ubiquitination, a key element in the essential cellular process of protein homeostasis, which is an exciting new target pathway for cancer treatment. Both scientific developments will be presented as posters at the EACR conference in Barcelona Spain on July 7-10 2012.
How do you measure the pain of a patient who can't communicate? A Rhode Island Hospital researcher studied an observational pain scale in cardiac surgery patients, and found that the Critical-Care Pain Observation Tool (CPOT) provided an accurate measure of a patient's pain level.
The thrombolytic drug alteplase, despite recent concerns, is safe and effective in routine clinical use when used within 3 hours of stroke onset, according to an observational study published in this week's issue of The Lancet.
A researcher at Montana State University has called for an innovative, new approach in developing a vaccine against genital herpes.
› Verified 7 days ago
Dr. Ravishankar Ramaswamy, MD, MS Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1440 Madison Avenue, New York, NY 10029 Phone: 212-659-8552 Fax: 212-860-9737 | |
Dr. Pietro Alessandro Ambrogio Canetta, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, Ph4-124, New York, NY 10032 Phone: 212-305-5020 Fax: 212-305-6692 | |
Dr. Rakhshan Mahmood Chida, M.D. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 327 E 17th St, New York, NY 10003 Phone: 212-420-5690 | |
Charles D Resor, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, New York, NY 10032 Phone: 212-305-2913 | |
Dr. Jacqueline Yuey Lonier, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1150 Saint Nicholas Ave, New York, NY 10032 Phone: 212-851-5494 | |
Dr. Sharon Uralil, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 550 1st Ave, New York, NY 10016 Phone: 212-263-3293 | |
Diana Kantor, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 775 9th Ave, New York, NY 10019 Phone: 212-586-1550 |